INTRODUCTION
============

Pancreatic cancer is a devastating malignancy with 1-year survival rate of \<18%.^[@R1]^ As the fourth leading cause of cancer-related death for both men and women in the United States,^[@R2]^ tumors progress rapidly with few specific symptoms and are thus at an advanced stage at diagnosis in most patients. Smoking, diabetes, and obesity are established risk factors for pancreatic cancer.^[@R3]--[@R5]^ Prevalence of overweight and obesity has rapidly increased during the last 2 decades. Obesity and overweight are commonly measured by body mass index (BMI), which is defined as weight in kilograms divided by height in meters squared. Obesity is defined by the World Health Organization (WHO) as BMI ≥30.0 kg/m^2^, and overweight is defined as BMI of 25.0 to 29.9 kg/m^2^. A most recent meta-analysis of 23 studies with 9504 cases suggests that higher BMI is a risk factor for pancreatic cancer with a relative risk (RR) of 1.10 (95% confidence interval \[CI\]: 1.07--1.14) for every 5-unit increment.^[@R6]^ However, prognostic effect of BMI still remains unclear for patients with established diagnosis of pancreatic cancer. Furthermore, results of published studies focusing on this topic are inconsistent. To explicate the question, we performed the meta-analysis to identify the relationship between BMI and OS in pancreatic cancer.

MATERIALS AND METHODS
=====================

Search Strategy
---------------

Two reviewers (Y-QS, JY) performed the search independently in PubMed database from its earliest available date to May 12, 2015. The following key words were used: pancreatic, pancreas, cancer, adenocarcinoma, tumor, neoplasm, mortality, survival, BMI, and body mass index. Boolean logic words (AND and OR) were jointly used to combine the key words. The EMBASE, Ovid, and Cochrane Library Databases were further searched for additional relevant articles. Full article was investigated if 1 of the 2 reviewers considered it potentially relevant. References of the relevant articles were further screened for earlier original studies. Disagreements were solved by group discussion (C-FX, Y-QS, JY, PD, J-QS).

Inclusion Criteria
------------------

Studies were considered eligible if they satisfied all the following items: research objects of individual study were patients diagnosed as having pancreatic cancer histologically or pathologically; relationship between BMI and OS was investigated; BMI was categorized as underweight (\<18.5 kg/m^2^), normal weight (18.5--24.9 kg/m^2^), overweight (25.0--29.9 kg/m^2^), and obese (≥30.0 kg/m^2^) in each study; HR and 95% CI were available for each BMI category (normal weight group was defined as reference, HR = 1) in individual study. Only full texts written in English were included.

Data Collection
---------------

We extracted the following information from each included article: author, year of publication, country, recruitment period, age, sample size, median OS, and HR with 95% CI for each BMI category. Authors were contacted for important missing information. We used multivariate Cox proportional HRs for the quantitative analysis. If multivariate HRs were not available and the corresponding authors did not respond to our request, then the univariate HRs were used instead. Data extraction was accomplished by 4 authors (Y-QS, JY, TX, X-HZ).

Quality Assessment
------------------

The Newcastle Ottawa scale (NOS), which was recommended by the Cochrane Non-Randomized Studies Methods Working Group, was used in this meta-analysis for quality assessment. NOS was designed to assess the quality of observational studies. It assessed study quality by 3 classifications, namely, selection, comparability, and outcome with a total score of nine stars. Among the 9 stars, 4 stars represented for the appropriate selection of exposure and nonexposure cohort participants, 2 stars represented for the comparability of cohort, and the last 3 stars described the assessment of outcome and follow-up. Studies that scored ≥5 of the 9 stars were considered to be of high quality.

Statistical Methods
-------------------

We performed analysis using a random-effect model in case that there was significant heterogeneity. We also performed sensitivity analysis to assess whether the summary estimates are robust to inclusion of studies. One study was removed every time, and the rest were analyzed to evaluate whether the results could have been affected significantly by a single study. Heterogeneity was assessed by value of *I*^2^. Publication bias was evaluated by the use of Begg funnel plot and Egger linear regression test. A pooled HR \>1 suggested that underweight, overweight, or obesity predicted an unfavorable prognosis for pancreatic cancer patients. Oppositely, a pooled HR \<1 suggested a favorable prognosis for those patients. It was regarded as statistically significant if the 95% CI of HR did not overlap 1. All *P* values were 2-sided. *P* \< 0.05 was regarded as statistically significant. All analyses were performed using the Stata version 12.0 software (StataCorp, College Station, TX, [http://www.stata.com](http://www.stata.com/)). Given that our study was a review of previous published studies, ethical approval or patient consent was not required.

RESULT
======

Study Characteristics
---------------------

The search strategy identified 212 articles, of which 10 met the inclusion criteria and were finally included (Figure [1](#F1){ref-type="fig"}). No additional relevant articles were yielded in EMBASE, Ovid, and Cochrane Library Databases. Eight studies were excluded because of the absence of HR^[@R7],[@R8]^ or different reference groups of BMI.^[@R9]--[@R14]^ All the 10 included studies were cohort analysis containing a total of 6801 patients recruited between 1982 and 2010, with a sample size ranging from 314 to 1861. Among all the studies, 5 studies explicated the impact of adult BMI on pancreatic cancer survival,^[@R15]--[@R19]^ for which OS was calculated from the date of pathological diagnosis to the date of death or last follow-up visit, whereas the remaining 5 focused on BMI at diagnosis^[@R20],[@R21]^ or before operation.^[@R22]--[@R24]^ For the 5 studies, OS was calculated from the date of diagnosis or surgery.^[@R20]--[@R24]^ According to the different points of BMI, we renamed the 2 groups as adult BMI group and BMI at diagnosis group, respectively. In the former group, usual adult weight and height available from questionnaires were used for calculating BMI. In the latter group, BMI was calculated by weight and height at diagnosis or measured by physical examination before operation. Characteristics and important information of relevant studies are listed in Table [1](#T1){ref-type="table"}. Quality assessment of studies is shown in Table [2](#T2){ref-type="table"}.
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Meta-analysis
-------------

### Overweight or Obesity Versus Normal BMI

Meta-analysis was performed in the adult BMI group and BMI at diagnosis group in a random-effect model. To determine the relationship between adult BMI and OS, meta-analysis was conducted for subgroups of overweight and obesity, respectively. Results informed that adult overweight was not statistically significantly associated with OS (HR: 1.00, 95% CI: 0.92--1.08, *P* = 0.560, *I*^2^ = 0.0%, Figure [2](#F2){ref-type="fig"}), whereas OS was significantly reduced in obesity subgroup (HR: 1.29, 95% CI: 1.17--1.41), with no obvious heterogeneity (*P* = 0.437, *I*^2^ = 0.0%, Figure [2](#F2){ref-type="fig"}). Compared with normal BMI, patients with BMI ≥25.0 kg/m^2^ survived obviously shorter with a 15% higher risk of death (HR: 1.15; 95% CI: 1.03--1.27, *P* = 0.010, *I*^2^ = 58.2%, Figure [2](#F2){ref-type="fig"}). Meta-analysis was performed to determine the impact of BMI at diagnosis. Results suggested that overweight and obesity both failed to result in an altered risk of death (HR: 1.10; 95% CI: 0.83--1.38 and HR: 1.10; 95% CI: 0.78--1.42, respectively, Figure [3](#F3){ref-type="fig"}).

![Forest plot showed the association between adult overweight/obesity and overall survival (OS) for pancreatic cancer. Random-effect model was used. For each study, the estimates of hazard ratio (HR) and 95% confidence interval (CI) were plotted with a box and a horizontal line. Closed diamond indicates pooled HR and 95% CI (1: overweight, 2: obesity).](medi-95-e3305-g004){#F2}

![Forest plot showed the association between overweight/obesity at diagnosis and overall survival (OS) for pancreatic cancer. Random-effect model was used (1: overweight, 2: obesity).](medi-95-e3305-g005){#F3}

Dose--response Meta-analysis
----------------------------

Dose--response meta-analysis was also performed for each group. Analysis from the 5 cohort studies about the relationship between adult BMI and overall survival (OS) showed an increased death risk of 1.11 (95% CI: 1.05--1.18) for every 5-kg/m^2^ increase in BMI (Figure [4](#F4){ref-type="fig"}). As shown in Figure [5](#F5){ref-type="fig"}, BMI at diagnosis showed no significant dose--response relationship to survival outcome of pancreatic cancer patients with an HR of 1.07 (95% CI: 0.85--1.30, *I*^2^ = 16.6%, *P* = 0.309). In consideration to the significant heterogeneity (Figure [5](#F5){ref-type="fig"}), we performed a subgroup analysis by excluding those studies^[@R20],[@R23],[@R24]^ not providing multivariate HR. However, no significant relationship was observed with an HR of 0.97 (95% CI: 0.58--1.35). Studies of Kasenda et al and Pelucchi et al were separated and analyzed as a subgroup, as the rest^[@R22]--[@R24]^ all focused on relationship between BMI and OS of pancreatic cancer patients who underwent operation. Results also suggested no significant relationship between BMI and survival for each subgroup (HR: 0.91, 95% CI: 0.74--1.08 and HR: 1.35, 95% CI: 0.97--1.73, respectively), which is shown in Figure [6](#F6){ref-type="fig"}.

![Dose--response meta-analysis for adult BMI group. Random-effect model was used. For each study, the estimates of dose-associated hazard ratio (HR) and 95% confidence interval (CI) were plotted with a box and a horizontal line. Closed diamond indicates pooled HR and 95% CI.](medi-95-e3305-g006){#F4}

![Dose--response meta-analysis for body mass index (BMI) at diagnosis group. Random-effect model was used. For each study, the estimates of dose-associated hazard ratio (HR) and 95% confidence interval (CI) were plotted with a box and a horizontal line. Closed diamond indicates pooled HR and 95% CI.](medi-95-e3305-g007){#F5}

![Dose--response meta-analysis for subgroups of BMI at diagnosis group studies.(1: preoperative BMI, 2:BMI at diagnosis).](medi-95-e3305-g008){#F6}

Sensitivity Analysis
--------------------

In sensitivity analysis, one study was removed at a time and the rest were analyzed. The pooled HRs ranged from 1.10 to 1.14 for adult BMI group and from 0.97 to 1.15 for BMI at diagnosis group. Results of sensitivity analysis are detailed in Table [3](#T3){ref-type="table"}. For the adult BMI group, the pooled estimates were robust and not influenced by a single study. However, for the BMI at diagnosis group, HRs ranged from 0.97 to 1.15 with 95% CIs all overlapping 1. This finding indicated that no statistically significant relationship was observed between BMI at diagnosis and OS.
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Publication Bias
----------------

Publication bias was assessed by use of Egger regression test and Begg funnel plot. Begg funnel plot for both groups revealed no obvious publication bias (Figures [7](#F7){ref-type="fig"}A and 8A). Further confirmation by use of Egger regression test also failed to find evidence of publication bias in both former group (*t* = 0.83, *P* = 0.465) and latter group (*t* = 1.13, *P* = 0.341, Figure [7](#F7){ref-type="fig"}B, 8B).

![Begg funnel plot and Egger linear regression test for adult body mass index (BMI) group studies. (A: Begg funnel plot, B: Egger linear regression).](medi-95-e3305-g010){#F7}

![Begg funnel plot and Egger linear regression test for body mass index (BMI) at diagnosis group studies.(A: Begg funnel plot, B: Egger linear regression).](medi-95-e3305-g011){#F8}

DISCUSSION
==========

Overweight/obesity and its related morbidities are a growing health problem claiming 2.8 million lives annually according to the WHO 2010 global report.^[@R25]^ Obesity has been found to be associated with a wide array of morbidities, including cardiovascular disease, chronic kidney disease, sleeping disorder, type 2 diabetes, and several forms of cancer. Relationship between obesity and risk of pancreatic cancer has been discussed for decades. Four meta-analyses^[@R6],[@R26]--[@R28]^ and 3 pooled analyses^[@R29]--[@R31]^ have attempted to explicate the question, evaluating the risk either in dose--response relationship or according to BMI categories. A recent review summarized that obese individuals have an RR ranging from 1.19 to 1.47, when compared with those of normal weight, regardless of diabetes or smoking status.^[@R32]^

Obesity is considered to be an adverse prognostic factor in malignancies, such as breast^[@R33]^ and colon cancers^[@R34]^. Prognostic influence of obesity on pancreatic cancer has also been searched in recent years. However, the role of obesity as a prognostic factor of pancreatic cancer is still unclear. Thus, we conducted the meta-analysis to identify the prognostic role of BMI on survival from pancreatic cancer. Results indicated that obesity in adulthood was associated with a significantly worse survival outcome, suggesting that obesity may be a potential important prognostic factor for pancreatic cancer. In addition, compared with normal BMI, increased adult BMI was related to higher risk of death with 11% percentage for every 5-unit increment.

No statistically significant relationship between preoperative obesity and survival is shown in Figure [6](#F6){ref-type="fig"}. Although not included in the analysis, many studies made effort on this topic. A study reported that patients with more intra-abdominal fat demonstrated worse OS (individuals in the second quartile showed a 4-fold increase in likelihood of death relative to the lowest quartile), though in a nonlinear fashion.^[@R11]^ A recent study reported that obesity did not impact operative complexity or length of stay, but resulted in a shortened survival for patients with pancreatic cancer undergoing pancreatoduodenectomy.^[@R7]^ Fleming et al^[@R13]^ summarized that obese patients with a BMI of \>35 kg/m^2^ are more likely to have decreased survival after surgical resection, whereas Benns et al^[@R12]^ found no significant difference in OS among patients with pancreatic cancer undergoing various types of operations (obese patients had an OS of 19.8 months compared with nonobese patients who had an OS of 23.5 months, *P* = 0.46). Prognostic effect of preoperative obesity on survival after operation needed further investigation.

To our knowledge, this study is the first meta-analysis evaluating the effect of BMI on survival from pancreatic cancer. However, limitations of our study should be addressed. First, several relevant studies were not primarily designed to monitor the effect of BMI on survival. Pelucchi et al^[@R21]^ considered data from 2 previous hospital-based case-control studies on risk factors for pancreatic cancer. Cases in analysis of Olson et al^[@R17]^ came from an ongoing hospital-based case-control study and Familial Pancreatic Cancer Registry at Memorial Sloan-Kettering Cancer Center. Second, credible conclusion established on more studies was necessary because of the relative small sample size of the current meta-analysis. Third, all included studies were from the United States or European developed countries. Compared with developing countries, techniques, devices, therapies, and patient population were vastly different in other countries. Collection of information from developed countries may help in investigating the topic more comprehensively and thoroughly. Cancer stage and treatments, such as surgery and chemotherapy, were important confounding factors for OS, and not all the studies provide the information.

Weight loss, which could influence the results of the included studies, was not considered. As we know, loss of weight was usual for pancreatic cancer patients either before or after diagnosis. Dalal et al^[@R35]^ suggested that obese patients experienced higher losses in weight, skeletal muscle, and visceral adipose tissue, which may contribute to poorer survival in pancreatic cancer patients. Choi et al^[@R9]^ also suggested that weight loss at diagnosis and during first-line chemotherapy was associated with shortened OS (HR: 1.300; *P* = 0.012 and HR: 1.367; *P* = 0.010, respectively). Furthermore, limited information was available on the possible joint effect of diabetes and obesity on survival. Diabetes, which often coexists with obesity, has been found to be associated with increased risk of pancreatic cancer, but little is known about its influence on survival. HR was adjusted for diabetes status in 4 studies only,^[@R15]--[@R18]^ and Gong et al^[@R18]^ suggested a poorer survival of obese diabetics as compared with obese patients without diabetes. Joint effects of obesity and diabetes on survival from pancreatic cancer require further identification.

Mechanisms behind the observation that obesity in adulthood is associated with decreased post-diagnostic survival have not been clarified thoroughly. As pancreatic cancer progresses rapidly, the chronic comorbidity associated with obesity, such as cardiovascular disease, can hardly explain the reduced survival. Increased insulin resistance may be the pathogenic mechanism between obesity and reduced OS in patients with pancreatic cancer.^[@R36]^ In obese individuals, the amount of glycerol, hormones, nonesterified fatty acids, cytokines, proinflammatory markers, and other substances that are involved in the development of insulin resistance is increased.^[@R37]^ To maintain normal blood sugar, islet β-cells secrete insulin compensatorily. In a status of hypersinulinemia, increased circulating level of insulin-like growth factor-1 induces proliferation and inhibits apoptosis of pancreatic cancer cells, thus contributing to tumorigenesis. In addition, DNA damage pathways, adipokines such as leptin,^[@R38]^ and proinflammatory environment induced by obesity^[@R39]^ may also contribute to tumorigenesis, angiogenesis, and metastasis and then resulted in a worse survival outcome. However, BMI at the time of diagnosis or operation showed no obvious effect on survival outcome. Overweight or obese patients possibly experienced less loss of weight and may be more tolerable to tumor burden, chemotherapy, and operation.

For patients undergoing pancreaticoduodenectomy, which is a major surgical procedure involving resection of the duodenum, the pancreatic head, uncinate process, and the distal common bile duct, complications, such as fistula, intra-abdominal hemorrhage and infection, and gastrointestinal bleeding, were usual and may also contribute to death. Patients undergoing surgery experience different degrees of weight loss and malnutrition, which increases the risk of postoperative complications and mortality. Possibility of intraoperative hemorrhage, incision infection, postoperative lower extremity deep venous thrombosis, pulmonary embolism, and metabolic disorder is relatively higher in obese patients. Whether obesity is related to survival after operation for patients suffering from pancreatic cancer needs further research.

In conclusion, obesity in adulthood is related to an abbreviated survival from pancreatic cancer. Higher adult BMI is also associated with a worse survival outcome in a dose--response relationship. However, BMI at diagnosis has not shown any clear relationship to survival outcome of pancreatic cancer. More studies are needed to validate this finding and the mechanism behind the observation should be evaluated in further studies.

Abbreviations: BMI = body mass index, CI = confidence interval, HR = hazard ratio, NOS = Newcastle Ottawa scale, OS = overall survival.
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